Fig S3: **Biomarker and immune phenotype analysis**



Responses were assessed in accordance with Response Evaluation Criteria in Solid Tumors 1.1 by independent review committee. RNAseq analysis was performed for 25 patient tumor samples. Immune phenotype was determined from available H&E and IHC samples. Patients who withdrew consent (n=1), with no sample for analysis (n=3), or failed quality control (n=1) were excluded from the analysis in panels (A-F). H&E, hematoxylin